Actionable news
All posts from Actionable news
Actionable news in NVCR: NovoCure Ltd,

Novocure to Offer On Demand Optune Certification Training for the Radiation Oncology Community at ASTRO 2015

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today it will offer on demand Optune certification training for the radiation oncology community at the American Society for Therapeutic Radiology and Oncology (ASTRO) 57th Annual Meeting in San Antonio, Texas from October 18 through October 20, 2015. Optune was approved by the FDA on October 5, 2015 for the treatment of newly diagnosed glioblastoma (GBM) in combination with temozolomide. Optune’s Instructions for Use (IFU) require that prescribing medical personnel complete a training course provided by Novocure. Novocure is committed to making this training widely available for radiation oncologists, given their critical role in the treatment of newly diagnosed GBM patients.

“Both Novocure and radiation oncologists treat glioblastoma with a physical modality and we believe there is a natural fit for us to work together to bring Tumor Treating Fields therapy to patients.”

Tweet this

Optune is the first FDA-approved therapy in more than a decade to demonstrate statistically significant extension of overall survival in newly diagnosed GBM. The two-year survival rate among patients treated with Optune in combination with temozolomide was 50% higher than in patients treated with temozolomide alone. No significant additive systemic toxicity was observed in the trial, and patients maintained stable quality-of-life, cognitive function and activities of daily living while using Optune.

“We are pleased to offer such a convenient training opportunity for radiation oncologists at ASTRO,” said Peter Melnyk, Novocure’s Chief Commercial Officer. “Novocure is committed to helping patients with glioblastoma and we know that the radiation oncology community will be an invaluable partner as we work together to bring this life-extending therapy to patients with newly diagnosed GBM.”

Certification training will be offered on location Sunday, October 18 through Tuesday, October 20, 2015. A sign-up sheet will be available at the Novocure exhibit, booth 1759.

Additional Novocure Activities at ASTRO

In addition to the certification training, Novocure will have four poster presentations describing the latest aspects of Tumor Treating Fields (TTFields) therapy at the meeting. Details on the poster presentations are as...